Ronald W. Barrett
CIK: 0001326330
Associated companies
Transaction History
| JANX | ▲ Buy | Grant | 5,500 | $0 | 6/11/2026 | View on chart |
| JANX | ▲ Buy | Grant | 3,750 | $0 | 6/11/2025 | View on chart |
| JANX | ▲ Buy | Grant | 2,500 | $0 | 6/26/2024 | View on chart |
| JANX | ▲ Buy | Grant | 5,500 | $0 | 6/11/2026 | View on chart |
| JANX | ▲ Buy | Grant | 3,750 | $0 | 6/11/2025 | View on chart |
| JANX | ▲ Buy | Grant | 2,500 | $0 | 6/26/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program
The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program. The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.